<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>neurology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>neurology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="An efficient design for whole genome trio sequencing identifies key variants in rare neurological disorder cases
Authors: Ramsey, K.; Kruglyak, S.; Naymik, M.; Lajoie, B. R.; Wiseman, K. N.; Sanchez-Castillo, M.; Billings, S.; Jepsen, W.; Huentelman, M.; Narayanan, V.
Score: 514.2, Published: 2023-10-19 DOI: 10.1101/2023.10.13.23296768
We sequenced nine trios in which the probands in an underserved population were affected by a rare and undiagnosed disorder with neurological features. Sequencing was performed with one trio per flowcell on a benchtop sequencing instrument, leveraging the design of sequencing the proband at twice the coverage of the parents.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/neurology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="neurology" />
<meta property="og:description" content="An efficient design for whole genome trio sequencing identifies key variants in rare neurological disorder cases
Authors: Ramsey, K.; Kruglyak, S.; Naymik, M.; Lajoie, B. R.; Wiseman, K. N.; Sanchez-Castillo, M.; Billings, S.; Jepsen, W.; Huentelman, M.; Narayanan, V.
Score: 514.2, Published: 2023-10-19 DOI: 10.1101/2023.10.13.23296768
We sequenced nine trios in which the probands in an underserved population were affected by a rare and undiagnosed disorder with neurological features. Sequencing was performed with one trio per flowcell on a benchtop sequencing instrument, leveraging the design of sequencing the proband at twice the coverage of the parents." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/neurology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-10-22T10:37:23+00:00" />
<meta property="article:modified_time" content="2023-10-22T10:37:23+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="neurology"/>
<meta name="twitter:description" content="An efficient design for whole genome trio sequencing identifies key variants in rare neurological disorder cases
Authors: Ramsey, K.; Kruglyak, S.; Naymik, M.; Lajoie, B. R.; Wiseman, K. N.; Sanchez-Castillo, M.; Billings, S.; Jepsen, W.; Huentelman, M.; Narayanan, V.
Score: 514.2, Published: 2023-10-19 DOI: 10.1101/2023.10.13.23296768
We sequenced nine trios in which the probands in an underserved population were affected by a rare and undiagnosed disorder with neurological features. Sequencing was performed with one trio per flowcell on a benchtop sequencing instrument, leveraging the design of sequencing the proband at twice the coverage of the parents."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "neurology",
      "item": "https://trxiv.yorks0n.com/posts/neurology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "neurology",
  "name": "neurology",
  "description": "An efficient design for whole genome trio sequencing identifies key variants in rare neurological disorder cases\nAuthors: Ramsey, K.; Kruglyak, S.; Naymik, M.; Lajoie, B. R.; Wiseman, K. N.; Sanchez-Castillo, M.; Billings, S.; Jepsen, W.; Huentelman, M.; Narayanan, V.\nScore: 514.2, Published: 2023-10-19 DOI: 10.1101/2023.10.13.23296768\nWe sequenced nine trios in which the probands in an underserved population were affected by a rare and undiagnosed disorder with neurological features. Sequencing was performed with one trio per flowcell on a benchtop sequencing instrument, leveraging the design of sequencing the proband at twice the coverage of the parents.",
  "keywords": [
    
  ],
  "articleBody": " An efficient design for whole genome trio sequencing identifies key variants in rare neurological disorder cases\nAuthors: Ramsey, K.; Kruglyak, S.; Naymik, M.; Lajoie, B. R.; Wiseman, K. N.; Sanchez-Castillo, M.; Billings, S.; Jepsen, W.; Huentelman, M.; Narayanan, V.\nScore: 514.2, Published: 2023-10-19 DOI: 10.1101/2023.10.13.23296768\nWe sequenced nine trios in which the probands in an underserved population were affected by a rare and undiagnosed disorder with neurological features. Sequencing was performed with one trio per flowcell on a benchtop sequencing instrument, leveraging the design of sequencing the proband at twice the coverage of the parents. The reduced coverage in the parents led to sequencing efficiencies while retaining the benefits of trio sequencing: the ability to discover de novo variants and the ability to trace inheritance patterns of rare variants. Once the sequencing data was generated, our two teams used independent informatics pipelines for variant calling and interpretation. In five of the nine cases, both teams found a single SNV or small indel that was deemed causal pending clinical validation. In three of the nine cases, neither team had a significant finding. In the final case, an additional scan for large CNVs performed by one of the teams identified a de novo deletion and duplication in the proband which is the likely cause of the underlying disease. The results across cases with significant findings showed a variety of affected genes (CFAP52, DYNC1H1, FANCE, TCF4, and TOP3A), variant types, and inheritance patterns. All findings were clinically validated, after which the families were counseled about disease management, current research studies (i.e. gene therapy), and family planning. With six of nine families receiving findings, the study demonstrated an efficient and effective trio sequencing design strategy.\nTransferability of a European-derived Alzheimer Disease Genetic Risk Score across Multi-Ancestry Populations.\nAuthors: Nicolas, A.; Grenier-Boley, B.; Sherva, R.; Kim, Y.; Kikuchi, M.; de Rojas, i.; Dalmasso, C.; Zhou, X.; Le Guen, Y.; Arboleda-Bustos, C. E.; Camargos Bicalho, M. A.; Guerchet, M.; van de Lee, S.; Goss, M.; castillo, a.; bellenguez, C.; Kucukali, F.; Satizabal Barrera, C.; Fongang, B.; yang, Q.; Peters, O.; Schneider, A.; Dichgans, M.; Rujescu, D.; Scherbaum, N.; Deckert, J.; Riedel-Heller, S.; Hausner, L.; Molina Porcel, L.; Duzel, E.; Grimmer, T.; Wiltfang, J.; Heilmann-Heimbach, S.; Moebus, S.; Tegos, T.; Scarmeas, N.; Dols-icardo, O.; Moreno, F.; Perez-Tur, J.; Bullido, M. J.; Pastor, P.; S\nScore: 6.8, Published: 2023-10-19 DOI: 10.1101/2023.10.17.23297061\nWe built a genetic risk score (GRS) from the most complete landscape of the Alzheimer disease (AD) genetics. We extended its analysis in 16 European countries and observed a consistent association of this GRS with AD risk, age at onset and cerebrospinal fluid (CSF) AD biomarker levels regardless of the Apolipoprotein E (APOE) genotype. This GRS was also associated with AD risk (independently of APOE) with a decreasing order of magnitude in those with an European-American, North-African, East-Asian, Latin-American, African-American background respectively. No association of the GRS to AD was seen in sub-Saharan African and Indian populations. This GRS captures information specific to AD as its association decreases as the diagnosis broadens. In conclusion, a simple GRS captures shared genetic information specific to AD between multi-ancestry populations. However, more population diversity is needed to better understand the AD genetic complexity across populations.\nSalience network and cognitive impairment in Parkinson's disease\nAuthors: Yeager, B. E.; Twedt, H. P.; Bruss, J.; Schultz, J.; Narayanan, N. S.\nScore: 5.2, Published: 2023-10-14 DOI: 10.1101/2023.10.13.23296825\nParkinsons disease (PD) is a neurodegenerative disease with cognitive as well as motor impairments. While much is known about the brain networks leading to motor impairments in PD, less is known about the brain networks contributing to cognitive impairments. Here, we leveraged resting-state functional magnetic resonance imaging (rs-fMRI) data from the Parkinsons Progression Marker Initiative (PPMI) to examine network dysfunction in PD patients with cognitive impairment. We tested the hypothesis that cognitive impairments in PD involve altered connectivity of the salience network (SN), a key cortical network that detects and integrates responses to salient stimuli. We used the Montreal Cognitive Assessment (MoCA) as a continuous index of coarse cognitive function in PD. We report two major results. First, in 82 PD patients we found significant relationships between lower intra-network connectivity of the frontoparietal network (FPN; comprising the dorsolateral prefrontal and posterior parietal cortices bilaterally) with lower MoCA scores. Second, we found significant relationships between lower inter-network connectivity between the SN and the basal ganglia network (BGN) and the default mode network (DMN) with lower MoCA scores. These data support our hypothesis about the SN and provide new insights into the brain networks contributing to cognitive impairments in PD. HighlightsO_LICognitive dysfunction is a prominent clinical symptom in Parkinsons disease C_LIO_LIFunctional connectivity of the salience network is important for cognition C_LIO_LISalience network dynamics are altered in patients with Parkinsons disease C_LIO_LISalience network connectivity with other networks is linked to worse cognition in PD C_LI\nLongitudinal prevalence of neurogenic orthostatic hypotension in the idiopathic Parkinson Progression Marker Initiative (PPMI) cohort.\nAuthors: Beach, P. A.; McKay, J.\nScore: 2.2, Published: 2023-10-17 DOI: 10.1101/2023.10.16.23297107\nBackgroundReported orthostatic hypotension (OH) prevalence in Parkinson disease (PD) varies widely, with few studies evaluating specifically neurogenic-OH (nOH). The ratio of orthostatic heart rate (HR) to systolic blood pressure (SBP) change ({Delta}) is a valid screening method to stratify nOH/non-nOH but had minimal epidemiologic application. ObjectiveTo estimate the prevalence of nOH and non-nOH in the PPMI using the {Delta}HR/{Delta}SBP ratio and examine associations between nOH and various motor and non-motor measures. MethodsLongitudinal orthostatic vitals and motor and non-motor measures were extracted (baseline-month 48). Patients were consensus criteria classified as OH+/-, with {Delta}HR/{Delta}SBP sub-classification to nOH ({Delta}HR/{Delta}SBP\u003c0.5) or non-nOH (ratio[\u0026ge;]0.5). Prevalence was determined across visits. Independent linear mixed models tested associations between nOH/non-nOH and clinical variables. ResultsOf N=907 PD with baseline orthostatic vitals, 3.9% and 1.8% exhibited nOH and non-nOH, respectively. Prevalence of nOH/non-nOH increased yearly (P=0.012, chi-square), though with modest magnitude (baseline: 5.6% [95% CI: 4.3-7.3%]; month 48: 8.6% [6.4-11.5%]). nOH patients were older than PD with no OH and nOH was associated with greater impairment of motor and independent functioning than non-nOH/OH-groups. Cognitive function and typical OH symptoms were worse in PD+OH, generally. ConclusionsnOH prevalence was greater than non-nOH in the PPMI early PD cohort, with modest prevalence increase over time. Our findings are consistent with prior studies of larges cohorts that evaluated nOH, specifically. Early PD with nOH were likelier to be older and suffer from greater motor and functional impairment, but OH presence was generally associated with more cognitive impairment.\nMapping the multidimensional geometric landscape of graded phenotypic variation and progression in neurodegenerative syndromes\nAuthors: Ramanan, S.; Akarca, D.; Henderson, S. K.; Rouse, M.; Allinson, K.; Patterson, K.; Rowe, J.; Lambon Ralph, M. A.\nScore: 6.7, Published: 2023-10-12 DOI: 10.1101/2023.10.11.23296861\nClinical variants of Alzheimers disease (AD) and frontotemporal lobar degeneration (FTLD) display a spectrum of cognitive-behavioural changes varying between individuals and over time. Understanding the landscape of these graded individual-/group-level longitudinal variations is critical for precise phenotyping; however, this remains challenging to model. Addressing this challenge, we leverage the National Alzheimers Coordinating Center database to derive a unified geometric framework of graded AD/FTLD longitudinal phenotypic variation. Using three time-point, cognitive-behavioural and clinical data from 390 typical, atypical and intermediate AD/FTLD variants, we apply advanced data-science approaches to derive low-dimensional geometric spaces capturing core features underpinning AD/FTLD clinical progression. Importantly, these geometries enable the assimilation and inter-relation of paradigmatic and mixed cases, capturing dynamic individual trajectories, and linking syndromic variability to neuropathology and key clinical end-points such as survival. This resultant mapping of dynamics underlying cognitive-behavioural evolution potentially holds paradigm-changing implications to predicting phenotypic diversification and phenotype-neurobiological mapping in AD/FTLD.\nHorizon Sham Adaptor: Unlocking the Potential of Dual-Functionality of Single TMS Coil for Real and Sham Stimulations\nAuthors: Memarian Sorkhabi, M.\nScore: 1.1, Published: 2023-10-19 DOI: 10.1101/2023.10.17.23297143\nThis paper introduces a new figure-of-eight TMS coil design capable of delivering both real and sham TMS stimulation using a single coil. The design, emitted clicking noise, and induced tactile sensation provide no discernible indication of whether it is in the real or sham state, making it suitable for double-blind studies. This coil family comprises the E-z Cool Coil and Air Film Coil (AFC) and is compatible with Magstim Horizon stimulators. This single-coil TMS setup enables the administration of either real or sham protocols without requiring coil replacement or physical repositioning. The transition between these states is achieved simply by replacing the adaptor between the coil connector and the TMS device.\nRurality Modifies the Association Between Symptoms and the Diagnosis of Amyotrophic Lateral Sclerosis\nAuthors: Hart, A. A.; Swenson, A.; Narayanan, N.; Simmering, J. E.\nScore: 1.2, Published: 2023-10-14 DOI: 10.1101/2023.10.13.23297024\nObjectiveWe utilized national claims-based data to identify the change in hazard of diagnosis of ALS following a possible ALS-related diagnosis (e.g., falls) and whether the change in hazard varies whether the patient lives in an urban or rural area. MethodsHealth insurance claims data from both the commercial insurance market and Medicare supplemental market were obtained from the Merative MarketScan Commercial Claims and Encounters and Medicare Coordination of Benefits databases. Individuals with a diagnosis of ALS were identified and matched on age, sex, and enrollment period to individuals without ALS. For all individuals, inciting events such as falls, muscle related symptoms, or bulbar symptoms were also extracted. We then used fixed-effects regression to estimate the risk of being diagnosed with ALS following one of these events controlling for urban-rural status. Additionally, we utilized interaction terms to evaluate the effect of rurality on odds of diagnosis. Results19,126 individuals with ALS were included with 96,126 controls. Patients with ALS were more likely than matched controls to live in an urban area (87 vs 85%). Of those with ALS 84% had a symptom code preceding their diagnosis as compared to 51% in the general population. The association between having any symptoms and future diagnosis of ALS remained statistically significant after adjustment for confounders and an odds ratio of nearly 5. Odds ratios for the individual symptoms varied from 1.2 to over 10. In all models, living in an urban area was associated with increased odds of diagnosis with ALS while the effect of having a symptom was smaller among urban dwellers. Urban dwellers who are diagnosed with ALS are diagnosed at younger ages. ConclusionsEarly diagnosis of ALS is vital for connecting patients with research and treatment options. These results suggest symptoms appear in the administrative health record potentially years before the diagnosis of ALS. Additionally, rural patients are diagnosed at later ages with a greater dependence on major symptoms than urban patients. These results highlight potential improvements for surveillance and screening for ALS.\nStriatal dopamine tone is positively associated with body mass index in humans as determined by PET using dual dopamine type-2 receptor antagonist tracers\nAuthors: Darcey, V. L.; Guo, J.; Chi, M.; Chung, S. T.; Courville, A. B.; Gallagher, I.; Herscovitch, P.; Howard, R.; La Noire, M.; Milley, L.; Schick, A.; Stagliano, M.; Turner, S.; Urbanski, N.; Yang, S.; Yim, E.; Zhai, N.; Zhou, M. S.; Hall, K. D.\nScore: 48.4, Published: 2023-09-28 DOI: 10.1101/2023.09.27.23296169\nThe relationship between adiposity and dopamine type-2 receptor binding potential (D2BP) in the human brain has been repeatedly studied for \u003e20 years with highly discrepant results, likely due to variable methodologies and differing study populations. We conducted a controlled inpatient feeding study to measure D2BP in the striatum using positron emission tomography with both [18F]fallypride and [11C]raclopride in pseudo-random order in 54 young adults with a wide range of body mass index (BMI 20-44 kg/m2). Within-subject D2BP measurements using the two tracers were moderately correlated (r=0.47, p\u003c0.001). D2BP was negatively correlated with BMI as measured by [11C]raclopride (r= -0.51; p\u003c0.0001) but not [18F]fallypride (r=-0.01; p=0.92) and these correlation coefficients were significantly different from each other (p\u003c0.001). Given that [18F]fallypride has greater binding affinity to dopamine type-2 receptors than [11C]raclopride, which is more easily displaced by endogenous dopamine, our results suggest that adiposity is positively associated with increased striatal dopamine tone.\n",
  "wordCount" : "1985",
  "inLanguage": "en",
  "datePublished": "2023-10-22T10:37:23Z",
  "dateModified": "2023-10-22T10:37:23Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/neurology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      neurology
    </h1>
    <div class="post-meta"><span>updated on October 22, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.13.23296768">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.13.23296768" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.13.23296768">
        <p class="paperTitle">An efficient design for whole genome trio sequencing identifies key variants in rare neurological disorder cases</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.13.23296768" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.13.23296768" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Ramsey, K.; Kruglyak, S.; Naymik, M.; Lajoie, B. R.; Wiseman, K. N.; Sanchez-Castillo, M.; Billings, S.; Jepsen, W.; Huentelman, M.; Narayanan, V.</p>
        <p class="info">Score: 514.2, Published: 2023-10-19 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.13.23296768' target='https://doi.org/10.1101/2023.10.13.23296768'> 10.1101/2023.10.13.23296768</a></p>
        <p class="abstract">We sequenced nine trios in which the probands in an underserved population were affected by a rare and undiagnosed disorder with neurological features. Sequencing was performed with one trio per flowcell on a benchtop sequencing instrument, leveraging the design of sequencing the proband at twice the coverage of the parents. The reduced coverage in the parents led to sequencing efficiencies while retaining the benefits of trio sequencing: the ability to discover de novo variants and the ability to trace inheritance patterns of rare variants. Once the sequencing data was generated, our two teams used independent informatics pipelines for variant calling and interpretation. In five of the nine cases, both teams found a single SNV or small indel that was deemed causal pending clinical validation. In three of the nine cases, neither team had a significant finding. In the final case, an additional scan for large CNVs performed by one of the teams identified a de novo deletion and duplication in the proband which is the likely cause of the underlying disease. The results across cases with significant findings showed a variety of affected genes (CFAP52, DYNC1H1, FANCE, TCF4, and TOP3A), variant types, and inheritance patterns. All findings were clinically validated, after which the families were counseled about disease management, current research studies (i.e. gene therapy), and family planning. With six of nine families receiving findings, the study demonstrated an efficient and effective trio sequencing design strategy.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.17.23297061">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.17.23297061" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.17.23297061">
        <p class="paperTitle">Transferability of a European-derived Alzheimer Disease Genetic Risk Score across Multi-Ancestry Populations.</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.17.23297061" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.17.23297061" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Nicolas, A.; Grenier-Boley, B.; Sherva, R.; Kim, Y.; Kikuchi, M.; de Rojas, i.; Dalmasso, C.; Zhou, X.; Le Guen, Y.; Arboleda-Bustos, C. E.; Camargos Bicalho, M. A.; Guerchet, M.; van de Lee, S.; Goss, M.; castillo, a.; bellenguez, C.; Kucukali, F.; Satizabal Barrera, C.; Fongang, B.; yang, Q.; Peters, O.; Schneider, A.; Dichgans, M.; Rujescu, D.; Scherbaum, N.; Deckert, J.; Riedel-Heller, S.; Hausner, L.; Molina Porcel, L.; Duzel, E.; Grimmer, T.; Wiltfang, J.; Heilmann-Heimbach, S.; Moebus, S.; Tegos, T.; Scarmeas, N.; Dols-icardo, O.; Moreno, F.; Perez-Tur, J.; Bullido, M. J.; Pastor, P.; S</p>
        <p class="info">Score: 6.8, Published: 2023-10-19 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.17.23297061' target='https://doi.org/10.1101/2023.10.17.23297061'> 10.1101/2023.10.17.23297061</a></p>
        <p class="abstract">We built a genetic risk score (GRS) from the most complete landscape of the Alzheimer disease (AD) genetics. We extended its analysis in 16 European countries and observed a consistent association of this GRS with AD risk, age at onset and cerebrospinal fluid (CSF) AD biomarker levels regardless of the Apolipoprotein E (APOE) genotype. This GRS was also associated with AD risk (independently of APOE) with a decreasing order of magnitude in those with an European-American, North-African, East-Asian, Latin-American, African-American background respectively. No association of the GRS to AD was seen in sub-Saharan African and Indian populations. This GRS captures information specific to AD as its association decreases as the diagnosis broadens. In conclusion, a simple GRS captures shared genetic information specific to AD between multi-ancestry populations. However, more population diversity is needed to better understand the AD genetic complexity across populations.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.13.23296825">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.13.23296825" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.13.23296825">
        <p class="paperTitle">Salience network and cognitive impairment in Parkinson&#39;s disease</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.13.23296825" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.13.23296825" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Yeager, B. E.; Twedt, H. P.; Bruss, J.; Schultz, J.; Narayanan, N. S.</p>
        <p class="info">Score: 5.2, Published: 2023-10-14 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.13.23296825' target='https://doi.org/10.1101/2023.10.13.23296825'> 10.1101/2023.10.13.23296825</a></p>
        <p class="abstract">Parkinsons disease (PD) is a neurodegenerative disease with cognitive as well as motor impairments. While much is known about the brain networks leading to motor impairments in PD, less is known about the brain networks contributing to cognitive impairments. Here, we leveraged resting-state functional magnetic resonance imaging (rs-fMRI) data from the Parkinsons Progression Marker Initiative (PPMI) to examine network dysfunction in PD patients with cognitive impairment. We tested the hypothesis that cognitive impairments in PD involve altered connectivity of the salience network (SN), a key cortical network that detects and integrates responses to salient stimuli. We used the Montreal Cognitive Assessment (MoCA) as a continuous index of coarse cognitive function in PD. We report two major results. First, in 82 PD patients we found significant relationships between lower intra-network connectivity of the frontoparietal network (FPN; comprising the dorsolateral prefrontal and posterior parietal cortices bilaterally) with lower MoCA scores. Second, we found significant relationships between lower inter-network connectivity between the SN and the basal ganglia network (BGN) and the default mode network (DMN) with lower MoCA scores. These data support our hypothesis about the SN and provide new insights into the brain networks contributing to cognitive impairments in PD.

HighlightsO_LICognitive dysfunction is a prominent clinical symptom in Parkinsons disease
C_LIO_LIFunctional connectivity of the salience network is important for cognition
C_LIO_LISalience network dynamics are altered in patients with Parkinsons disease
C_LIO_LISalience network connectivity with other networks is linked to worse cognition in PD
C_LI</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.16.23297107">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.16.23297107" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.16.23297107">
        <p class="paperTitle">Longitudinal prevalence of neurogenic orthostatic hypotension in the idiopathic Parkinson Progression Marker Initiative (PPMI) cohort.</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.16.23297107" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.16.23297107" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Beach, P. A.; McKay, J.</p>
        <p class="info">Score: 2.2, Published: 2023-10-17 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.16.23297107' target='https://doi.org/10.1101/2023.10.16.23297107'> 10.1101/2023.10.16.23297107</a></p>
        <p class="abstract">BackgroundReported orthostatic hypotension (OH) prevalence in Parkinson disease (PD) varies widely, with few studies evaluating specifically neurogenic-OH (nOH). The ratio of orthostatic heart rate (HR) to systolic blood pressure (SBP) change ({Delta}) is a valid screening method to stratify nOH/non-nOH but had minimal epidemiologic application.

ObjectiveTo estimate the prevalence of nOH and non-nOH in the PPMI using the {Delta}HR/{Delta}SBP ratio and examine associations between nOH and various motor and non-motor measures.

MethodsLongitudinal orthostatic vitals and motor and non-motor measures were extracted (baseline-month 48). Patients were consensus criteria classified as OH&#43;/-, with {Delta}HR/{Delta}SBP sub-classification to nOH ({Delta}HR/{Delta}SBP&lt;0.5) or non-nOH (ratio[&amp;ge;]0.5). Prevalence was determined across visits. Independent linear mixed models tested associations between nOH/non-nOH and clinical variables.

ResultsOf N=907 PD with baseline orthostatic vitals, 3.9% and 1.8% exhibited nOH and non-nOH, respectively. Prevalence of nOH/non-nOH increased yearly (P=0.012, chi-square), though with modest magnitude (baseline: 5.6% [95% CI: 4.3-7.3%]; month 48: 8.6% [6.4-11.5%]). nOH patients were older than PD with no OH and nOH was associated with greater impairment of motor and independent functioning than non-nOH/OH-groups. Cognitive function and typical OH symptoms were worse in PD&#43;OH, generally.

ConclusionsnOH prevalence was greater than non-nOH in the PPMI early PD cohort, with modest prevalence increase over time. Our findings are consistent with prior studies of larges cohorts that evaluated nOH, specifically. Early PD with nOH were likelier to be older and suffer from greater motor and functional impairment, but OH presence was generally associated with more cognitive impairment.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.11.23296861">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.11.23296861" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.11.23296861">
        <p class="paperTitle">Mapping the multidimensional geometric landscape of graded phenotypic variation and progression in neurodegenerative syndromes</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.11.23296861" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.11.23296861" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Ramanan, S.; Akarca, D.; Henderson, S. K.; Rouse, M.; Allinson, K.; Patterson, K.; Rowe, J.; Lambon Ralph, M. A.</p>
        <p class="info">Score: 6.7, Published: 2023-10-12 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.11.23296861' target='https://doi.org/10.1101/2023.10.11.23296861'> 10.1101/2023.10.11.23296861</a></p>
        <p class="abstract">Clinical variants of Alzheimers disease (AD) and frontotemporal lobar degeneration (FTLD) display a spectrum of cognitive-behavioural changes varying between individuals and over time. Understanding the landscape of these graded individual-/group-level longitudinal variations is critical for precise phenotyping; however, this remains challenging to model. Addressing this challenge, we leverage the National Alzheimers Coordinating Center database to derive a unified geometric framework of graded AD/FTLD longitudinal phenotypic variation. Using three time-point, cognitive-behavioural and clinical data from 390 typical, atypical and intermediate AD/FTLD variants, we apply advanced data-science approaches to derive low-dimensional geometric spaces capturing core features underpinning AD/FTLD clinical progression. Importantly, these geometries enable the assimilation and inter-relation of paradigmatic and mixed cases, capturing dynamic individual trajectories, and linking syndromic variability to neuropathology and key clinical end-points such as survival. This resultant mapping of dynamics underlying cognitive-behavioural evolution potentially holds paradigm-changing implications to predicting phenotypic diversification and phenotype-neurobiological mapping in AD/FTLD.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.17.23297143">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.17.23297143" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.17.23297143">
        <p class="paperTitle">Horizon Sham Adaptor: Unlocking the Potential of Dual-Functionality of Single TMS Coil for Real and Sham Stimulations</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.17.23297143" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.17.23297143" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Memarian Sorkhabi, M.</p>
        <p class="info">Score: 1.1, Published: 2023-10-19 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.17.23297143' target='https://doi.org/10.1101/2023.10.17.23297143'> 10.1101/2023.10.17.23297143</a></p>
        <p class="abstract">This paper introduces a new figure-of-eight TMS coil design capable of delivering both real and sham TMS stimulation using a single coil. The design, emitted clicking noise, and induced tactile sensation provide no discernible indication of whether it is in the real or sham state, making it suitable for double-blind studies. This coil family comprises the E-z Cool Coil and Air Film Coil (AFC) and is compatible with Magstim Horizon stimulators. This single-coil TMS setup enables the administration of either real or sham protocols without requiring coil replacement or physical repositioning. The transition between these states is achieved simply by replacing the adaptor between the coil connector and the TMS device.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.13.23297024">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.13.23297024" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.13.23297024">
        <p class="paperTitle">Rurality Modifies the Association Between Symptoms and the Diagnosis of Amyotrophic Lateral Sclerosis</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.13.23297024" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.13.23297024" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Hart, A. A.; Swenson, A.; Narayanan, N.; Simmering, J. E.</p>
        <p class="info">Score: 1.2, Published: 2023-10-14 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.13.23297024' target='https://doi.org/10.1101/2023.10.13.23297024'> 10.1101/2023.10.13.23297024</a></p>
        <p class="abstract">ObjectiveWe utilized national claims-based data to identify the change in hazard of diagnosis of ALS following a possible ALS-related diagnosis (e.g., falls) and whether the change in hazard varies whether the patient lives in an urban or rural area.

MethodsHealth insurance claims data from both the commercial insurance market and Medicare supplemental market were obtained from the Merative MarketScan Commercial Claims and Encounters and Medicare Coordination of Benefits databases. Individuals with a diagnosis of ALS were identified and matched on age, sex, and enrollment period to individuals without ALS. For all individuals, inciting events such as falls, muscle related symptoms, or bulbar symptoms were also extracted. We then used fixed-effects regression to estimate the risk of being diagnosed with ALS following one of these events controlling for urban-rural status. Additionally, we utilized interaction terms to evaluate the effect of rurality on odds of diagnosis.

Results19,126 individuals with ALS were included with 96,126 controls. Patients with ALS were more likely than matched controls to live in an urban area (87 vs 85%). Of those with ALS 84% had a symptom code preceding their diagnosis as compared to 51% in the general population. The association between having any symptoms and future diagnosis of ALS remained statistically significant after adjustment for confounders and an odds ratio of nearly 5. Odds ratios for the individual symptoms varied from 1.2 to over 10. In all models, living in an urban area was associated with increased odds of diagnosis with ALS while the effect of having a symptom was smaller among urban dwellers. Urban dwellers who are diagnosed with ALS are diagnosed at younger ages.

ConclusionsEarly diagnosis of ALS is vital for connecting patients with research and treatment options. These results suggest symptoms appear in the administrative health record potentially years before the diagnosis of ALS. Additionally, rural patients are diagnosed at later ages with a greater dependence on major symptoms than urban patients. These results highlight potential improvements for surveillance and screening for ALS.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.27.23296169">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.27.23296169" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.27.23296169">
        <p class="paperTitle">Striatal dopamine tone is positively associated with body mass index in humans as determined by PET using dual dopamine type-2 receptor antagonist tracers</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.27.23296169" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.27.23296169" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Darcey, V. L.; Guo, J.; Chi, M.; Chung, S. T.; Courville, A. B.; Gallagher, I.; Herscovitch, P.; Howard, R.; La Noire, M.; Milley, L.; Schick, A.; Stagliano, M.; Turner, S.; Urbanski, N.; Yang, S.; Yim, E.; Zhai, N.; Zhou, M. S.; Hall, K. D.</p>
        <p class="info">Score: 48.4, Published: 2023-09-28 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.27.23296169' target='https://doi.org/10.1101/2023.09.27.23296169'> 10.1101/2023.09.27.23296169</a></p>
        <p class="abstract">The relationship between adiposity and dopamine type-2 receptor binding potential (D2BP) in the human brain has been repeatedly studied for &gt;20 years with highly discrepant results, likely due to variable methodologies and differing study populations. We conducted a controlled inpatient feeding study to measure D2BP in the striatum using positron emission tomography with both [18F]fallypride and [11C]raclopride in pseudo-random order in 54 young adults with a wide range of body mass index (BMI 20-44 kg/m2). Within-subject D2BP measurements using the two tracers were moderately correlated (r=0.47, p&lt;0.001). D2BP was negatively correlated with BMI as measured by [11C]raclopride (r= -0.51; p&lt;0.0001) but not [18F]fallypride (r=-0.01; p=0.92) and these correlation coefficients were significantly different from each other (p&lt;0.001). Given that [18F]fallypride has greater binding affinity to dopamine type-2 receptors than [11C]raclopride, which is more easily displaced by endogenous dopamine, our results suggest that adiposity is positively associated with increased striatal dopamine tone.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
